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Nanocomposites as “stevedores” for co-delivery of multidrugs hold great promise in 19 
addressing the drawbacks of traditional cancer chemotherapy.  In this work, our strategy presents 20 
a new avenue for the stepwise release of two co-delivered agents into the tumor cells.  The 21 
hybrid nanocomposite consists of a pH-responsive chitosan (CS), a thermosensitive 22 
poly(N-vinylcaprolactam) (PNVCL) and a functionalized cell-penetrating peptide (H6R6).  23 
Doxorubicin (DOX) and oleanolic acid (OA) are loaded into the nanocomposite 24 
(H6R6-CS-g-PNVCL).  The system displayed a suitable size (~190 nm), a high DOX loading 25 
(13.2%) and OA loading efficiency (7.3%). The tumor microenvironment triggered the 26 
nanocomposite to be selectively retained in tumor cells, then releasing the drugs. Both in vitro and 27 
in vivo studies showed a significant enhancement in antitumor activity of the co-delivered system 28 
in comparison to mono-delivery.  This approach which relies on redox, pH and temperature 29 
effects utilizing co-delivery nanosystems may be beneficial for future applications in cancer 30 
chemotherapy. 31 
Keywords: chitosan; H6R6 peptide; triple sensitivity; controlled release; chemotherapy 32 
 33 
 34 
1. Introduction 35 
 36 
To date, cancer remains one of the most threatening intractable diseases in human medical 37 
history and although there are numerous treatments, chemotherapy still plays an irreplaceable role 38 
in treatment (X. Chen et al., 2019; J. Wang et al., 2019).  However, conventional chemotherapy 39 
exhibits many drawbacks such as poor water-solubility of the anticancer drugs, damaging 40 
side-effects on normal cells, the premature leakage of drugs from delivery systems, as well as the 41 
insignificant therapeutic effect when only a single drug is utilized.  Furthermore, long-term 42 
administration of chemotherapeutics can cause multidrug resistance (MDR) of tumor cells, which 43 
results in the failure of chemotherapy (Chen et al., 2016; Zhao et al., 2017; Zhou et al., 2018). 44 
Fortunately, various nanotechnologies have been introduced into drug delivery systems to solve 45 
some of these problems (Chai et al., 2019; Jin et al., 2019; Ke et al., 2019; Lang et al., 2019).  46 
The enhanced permeability and retention (EPR) effect of solid tumors can make it easier for 47 
nanocomposites of suitable size to accumulate in tumor tissues (Luo et al., 2019; Y. Zhang, Lu, et 48 
al., 2017), thereby facilitating the effective delivery of chemotherapy drugs.  In addition, tumor 49 
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cells possess their own peculiarities that provide many opportunities for cancer treatment 50 
(El-Sawy, Al-Abd, Ahmed, El-Say, & Torchilin, 2018), including an acidic microenvironment (J. 51 
Xiao et al., 2019; L. Xiao, Huang, Moingeon, Gauthier, & Yang, 2017; Y. Zhang, Dang, et al., 52 
2017), higher temperature within cancer cells (S. Niu et al., 2018) and greater  intracellular 53 
glutathione (GSH) concentration than that observed in normal cells (Hu et al., 2016; Yang et al., 54 
2019).  In recent years, specific tumor microenvironments have led to the design of an increasing 55 
number of nanodrug delivery systems to treat cancer.  For example, Wang’s group reported a pH 56 
and reduction-responsive polymeric lipid vesicle for the targeted delivery of doxorubicin (S. Wang 57 
et al., 2014).  Mao’s group designed a micelle to control the release of doxorubicin under a high 58 
GSH tumor microenvironment (Mao et al., 2018).  The use of such specialized treatments 59 
utilizing these particular tumor microenvironments have paved the way for novel targeted cancer 60 
chemotherapy. 61 
According to previous literature reports, chitosan (CS) has a variety of beneficial properties 62 
in vivo e.g. amphipathy, biocompatibility, biodegradability and biosafety (Galbiati et al., 2011).  63 
CS can inhibit bacterial infection, decrease inflammation (L. Sun et al., 2019),and is soluble in 64 
acidic solutions (Rosiere et al., 2018), thereby allowing it to respond to the slightly acidic 65 
microenvironment found in tumors.  There are also many applications of CS in the field of drug 66 
delivery, for example, Niu’s group developed a chitosan-based cascade-responsive doxorubicin 67 
delivery system to overcome some hard-to-treat cancers (Shiwei Niu, Williams, Wu, Wu, Zhang, 68 
Chen, et al., 2019) and Zhang’s group synthesized hyaluronic acid-grafted chitosan nanoparticles 69 
to improve delivery of paclitaxel for breast cancer therapy (X. Zhang et al., 2019).  70 
Poly(N-vinylcaprolactam) (PNVCL), a promising thermo-responsive polymer, shows a lower 71 
critical solution temperature (LCST) at ~32°C (Montes, Ortega, & Burillo, 2014) and the LCST 72 
can be tuned to a higher temperature by grafting on other hydrophilic polymers (Indulekha, 73 
Arunkumar, Bahadur, & Srivastava, 2017).  Therefore, PNVCL has been widely applied in drug 74 
delivery and thermo-triggered drug release systems (Prabaharan, Grailer, Steeber, & Gong, 2009).  75 
Several teams have taken advantage of the combination of CS and PNVCL for cancer theranostics 76 
(Shiwei Niu, Williams, Wu, Wu, Zhang, Chen, et al., 2019).  Active targeting of drug delivery 77 
systems can be enhanced by the use of cell-penetrating peptides (CPPs) which are well known 78 
short peptides that can assist in penetration of certain substances into cells through endocytosis 79 
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(Xu et al., 2019).  There are various reviews of therapeutic applications of CPPs in different 80 
tissues and organs (Gao et al., 2019; Hingorani et al., 2020; Liu et al., 2019; Wu et al., 2019).  81 
According to a recent report (P. Sun et al., 2017), the H6R6 peptide (amino acid sequence: 82 
KVRVRVRVDPTRVRERVK) is one of the CPPs showing remarkable mediating effects, which 83 
can facilitate the uptake of drug-loaded nanoparticles (NPs) by tumor cells.  An important factor 84 
in the mediation of endocytosis is the presence of an appropriate quantity of arginine amino acids 85 
in H6R6 peptide which renders it positively charged and as cell membranes are negatively charged 86 
the electrostatic interaction facilitates endocytosis (Perche, 2019).  Furthermore, the H6R6 87 
peptide increases intracellular uptake and helps NPs escape from the endosome/lysosome (P. Sun 88 
et al., 2017), which is advantageous for drugs diffusing into the cytoplasm to kill the tumors. 89 
On the other hand, cancer can also be treated with multiple chemotherapy drugs.  In 90 
addition to doxorubicin (DOX), oleanolic acid (OA) is an excellent naturally occurring anticancer 91 
agent with hepato-protective action (Tao et al., 2018).  Recent studies have shown that OA can 92 
inhibit the growth of leukemia, non-small-cell lung cancer (NSCLC) cell lines (Z. Chen et al., 93 
2019) and other malignant tumors (Silva et al., 2019; Takemura et al., 2011).  Furthermore, it has 94 
been shown that OA can address MDR (Shiwei Niu, Williams, Wu, Wu, Zhang, Zheng, et al., 95 
2019), so it may be highly beneficial to load nanocomposites with two drugs (DOX and OA) for 96 
broad-spectrum growth inhibition of tumors. 97 
In this current work, the nanocomposite was fabricated by reversible addition fragmentation 98 
chain transfer (RAFT) polymerization to form the thermo- and pH- sensitive copolymer 99 
(CS-g-PNVCL).  The H6R6 peptide was bound to the CS-g-PNVCL by reduction-sensitive 100 
disulfide bonds (-S-S-) to form H6R6-CS-g-PNVCL (self-assembly in aqueous solution) which 101 
had the hydrophilic H6R6 peptide on the outermost surface of the nanocomposite.  Finally, the 102 
hydrophobic chemotherapeutics (DOX and OA) were physically loaded into the hydrophobic core 103 
of the nanocomposite to obtain the drug co-delivery system (DOX/OA)@H6R6-CS-g-PNVCL. 104 
Therefore, the role of CS is to promote the disintegration of the nanocomposite in the acidic tumor 105 
microenvironment, the role of NVCL is to make the LCST of the nanocomposite be tuned to a 106 
higher temperature (close to the temperature of the tumor microenvironment), promoting the 107 
further disintegration of the nanocomposite in the temperature of the tumor microenvironment.   108 
Once the NPs reach the tumor cells, the outermost H6R6 peptide will detach from the NPs via 109 
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breakage of -S-S- bonds under the reductive tumor microenvironment. The combination of -S-S- 110 
bonds and the H6R6 peptide plays an important role in allowing the nanocomposite to stay in the 111 
tumor cells. Thereafter, the relatively high temperature and acidic conditions of the tumor further 112 
promote the disintegration of the hybrid nanocomposite, triggering release of the drugs. And the 113 
design of such nanocomposites and the strategy of dual-loaded drugs may provide a new direction 114 
in tumor chemotherapy. 115 
 116 
 117 
Scheme 1. (a) The self-assembly of H6R6-CS-g-PNVCL NPs.  (b) The enhanced penetration and retention effect 118 
ensures that the NPs remain in the tumor sites.  (c) The self-destructive behavior of NPs with triple sensitivity in 119 
the tumor microenvironment, releasing DOX and OA. 120 
 121 
2. Experimental details 122 
 123 
2.1. Materials, cell lines and animals 124 
 125 
Chitosan (CS, degree of deacetylation >95%, Mw 200 kDa), N,N-dimethylformamide (DMF) 126 
and acetic anhydride were sourced from the SinoPharm Chemical Reagent Co., Ltd (Shanghai, 127 
China).  N-Vinylcaprolactam (NVCL) and dialysis tubing were supplied by the Titan Technology 128 
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Co., Ltd (Shanghai, China).  Cys-H6R6 (peptide, sequence CKVRVRVRVDPTRVRERVK ) was 129 
purchased from DG Peptides Co., Ltd. (Hangzhou, China).  Doxorubicin (DOX, 98%), 130 
N-(3-dimethyl-aminopropyl)-N-ethylcarbodiimide hydrochloride (EDC), azobisisobutyronitrile 131 
(AIBN), S’-1-dodecyl-S’-(α, α’-dimethyl-α’’-acetic acid) trithiocarbonate (DDATC) and 132 
N-hydroxysuccinimide (NHS) were obtained from the Aladdin Reagent Co. (Shanghai, China).  133 
Deuterium oxide (D2O), Dimethyl sulfoxide-d6 (DMSO-d6), 4-(dimethyl-amino) pyridine 134 
(DMAP), N,N-dicyclohexylcarbodiimide (DCC), thioglycolic acid, glutathione (GSH) and 135 
oleanolic acid (OA) were procured from Sigma-Aldrich (St. Louis, MO, USA).  Dulbecco’s 136 
modified Eagle medium (DMEM), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 137 
(MTT), fetal bovine serum (FBS), McCoy’s 5A incomplete medium, 0.05% trypsin-EDTA, 0.25% 138 
trypsin (without EDTA), Hoechst 33342, calcein-AM, propidium iodide (PI), Annexin V-FITC/PI 139 
cell apoptosis analysis kit and phosphate buffered solution (PBS) were obtained from the 140 
Beyotime Institute of Biotechnology (Shanghai, China).  DiR 141 
(1,10-dioctadecyl-3,3,30,30-tetramethylindo- tricarbo cyanine iodide) was sourced from Biotium 142 
(Fremont, CA, USA).  All chemicals were of analytical grade and had no additional purification. 143 
Human ovarian cancer (SKOV3) cell line and human umbilical vein endothelial (HUVEC) 144 
cell line were obtained from the Chinese Academy of Sciences (CAS, Shanghai, China).  Female 145 
nude mice (4-5 weeks old) and Sprague-Dawley (SD) rats were procured from the Kunming 146 
Medical University (Kunming, China).  All animal care and handling was conducted in 147 
accordance with the Guide for the Care and Use of Laboratory Animals published by the US 148 
National Institutes of Health (NIH Publication No.8523, revised 1985).  The experimental 149 
protocols were reviewed and approved by the Animal Care and Use Committee of Kunming 150 
Medical University (ref: KMMU 2015002). 151 
 152 
2.2. Synthesis of H6R6-CS-g-PNVCL 153 
 154 
H6R6-CS-g-PNVCL was synthesized using the literature method with some modifications 155 
(Qian et al., 2019; Quinones, Peniche, & Peniche, 2018).  The procedure was that we introduced 156 
the hydrophobic NVCL into CS molecules by RAFT reagent grafting to generate a 157 
hydrophobic-hydrophilic balance promoting the copolymer (CS-g-PNVCL) self-assembly, then 158 
hydrophilic H6R6 peptide was modified on the outermost surface of the copolymer. Chitosan (CS, 159 
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5 g) was fully dissolved in aqueous acetic acid (250 mL, 1.0% w/w) and stirred with anhydrous 160 
ethanol (250 mL) until clarified, acetic anhydride (0.5 mL) was added and stirring continued at 161 
room temperature for 12 h.  An aqueous solution of NaOH (50 mL, 10% w/w) was added and the 162 
precipitate was removed by filtration and the resulting solution was lyophilized to obtain N-acetyl 163 
CS.  The N-CS-RAFT was prepared by dissolving N-acetyl CS (0.292 g) in DMF (30 mL) and 164 
stirring with DDACT (0.37 g), DCC (0.205 g) and DMAP (0.015 g) at room temperature for 40 h.  165 
Ultrapure ice water was added and the precipitate was dialyzed with a dialysis tubing (molecular 166 
weight cutoff (MWCO) = 3500 Da) for 3 d, followed by freeze-drying for 3 d, to produce the 167 
golden yellow N-acetyl CS-RAFT. 168 
The N-acetyl CS-RAFT (0.0468 g) was then dissolved in DMF (5 mL) and AIBN（0.0032 g）169 
and NVCL (1 g) were added and gently stirred in an oil bath at 60 °C under nitrogen until the 170 
reaction mixture was completely dissolved (about 4 h).  Ice-cold diethyl ether (50 mL) was 171 
poured into the reaction mixture about 12 h later to form a precipitate which was collected by 172 
filtration.  The precipitate was then dialyzed (MWCO = 3500 Da) for 3 d to remove any 173 
unreacted starting materials and then the dialyzed solution was freeze-dried to afford N-acetyl 174 
CS-g-PNVCL.  Finally, the N-acetyl groups were removed by hydrolysis for 24 h with aqueous 175 
NaOH (0.01 g NaOH in 0.09 mL H2O, pH=10) and the CS-g-PNVCL was collected by dialysis 176 
and drying. 177 
Finally, H6R6-CS-g-PNVCL was prepared by dissolving CS-g-PNVCL (0.05 g) in PBS 178 
buffer solution (30 mL, pH 7.4), reacting it with thioglycolic acid (20 mg) catalysed with EDC (20 179 
mg) and NHS (6.4 mg) and stirring under nitrogen at room temperature for 2 h.  180 
Cysteine-modified H6R6 peptide (0.04 g) was dissolved in PBS buffer solution (10 mL, pH 7.4) 181 
and slowly added dropwise into the above solution with stirring at room temperature in the dark 182 
under nitrogen for 24 h.  The solution were dialyzed (MWCO=3500 Da) for 3 d, and freeze-dried 183 
to obtain H6R6-CS-g-PNVCL. 184 
 185 
2.3. Drug loading and characterization  186 
 187 
The hydrophobic chemotherapeutics (DOX and OA) were physically loaded into the 188 
hydrophobic core of the nanocomposite. DOX (5 mg) and OA (5 mg) were dissolved in DMF (10 189 
mL) and H6R6-CS-g-PNVCL (30 mg) was dissolved in PBS solution (25 mL, pH 7.4) and the two 190 
8 
 
solutions were mixed and dispersed with ultrasonic assistance followed by stirring in the dark for 191 
24 h.  The resulting product was centrifuged (3,000 r/min) for 15 min and dialyzed (MWCO = 192 
3500 Da) for 3 d, then freeze-dried to obtain (DOX/OA)@H6R6-CS-g-PNVCL as a powder.  193 
The preparation of DOX@H6R6-CS-g-PNVCL was similar to that of 194 
(DOX/OA)@H6R6-CS-g-PNVCL except OA was added.  (DOX/OA)@CS-g-PNVCL was 195 
prepared without adding any cysteine-modified H6R6 peptide. 196 
A small amount of (DOX/OA)@H6R6-CS-g-PNVCL powder was dissolved in ultra-pure 197 
water and then centrifuged (11,000 r/min) for 1 h. The supernatant was collected and the amount 198 
of unencapsulated drugs were determined by UV-vis spectrophotometry (UNICO, China) using 199 
previously prepared calibration curves (Fig. S5). The encapsulation efficiency (EE) and drug 200 
loading (DL) of DOX were calculated using equation (1) and (2), respectively, and the 201 
encapsulation efficiency (EE’) and drug loading (DL’) of OA were calculated from equation (3) 202 
and (4), respectively. 203 
 204 
%EE = (DOXt - DOXf) / DOXt × 100%                        (1) 205 
%DL = (DOXt - DOXf) / G × 100%                           (2) 206 
%EE’ = (OAt - OAf) / OAt × 100%                            (3) 207 
%DL’ = (OAt - OAf) / G × 100%                              (4) 208 
 209 
DOXt is the total mass (mg) of DOX to fabricate the nanocomposite; DOXf is the mass (mg) of 210 
unencapsulated DOX in the supernatant; G is the total mass (mg) of the nanocomposite; OAt is the 211 
total mass (mg) of OA used to fabricate the nanocomposite; and OAf is the mass (mg) of 212 
unencapsulated OA in the supernatant. 213 
Fourier transform infrared (FT-IR) spectra were recorded using a Nicolet-Nexus 670 214 
spectrometer (Thermo Fisher, USA.) over the range 4000-500 cm-1 with the resolution of 2cm-1. 215 
To further confirm the successful preparation of NPs, 1H NMR spectra and 13C NMR spectra were 216 
obtained on a Bruker AVANCE 400 M spectrometer (Bruker, USA.) with D2O or DMSO-d6 as the 217 
solvent.  The size and morphology of (DOX/OA)@H6R6-CS-g-PNVCL were visualized using a 218 
transmission electron microscope (JEM 1200EX instrument, JOEL, Japan) and a scanning 219 
electron microscope (Nova TM Nano instrument, FEI, USA.).  The size distribution and zeta 220 
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potential of NPs were determined by dynamic light scattering (DLS) using a BI-200SM 221 
instrument (Brookhaven Instruments, USA.).  The thermogravimetric analysis (TGA) of the 222 
samples from 100 °C to 800 °C were recorded using a thermogravimetric analyzer (Netzsch TG 223 
209 F1 Libra, Germany). The LCST of the nanocomposites was recorded with a UV–vis 224 
spectrophotometer (PerkinElmer, Waltham, MA, USA), and the concentration of the sample 225 
dispersion is 0.5 mg/mL (pH 7.4). 226 
 227 
2.4. In vitro DOX and OA release  228 
 229 
The dialysis method was used to study the release behaviors of 230 
(DOX/OA)@H6R6-CS-g-PNVCL at different temperatures and pH (mimics normal cell and 231 
specific tumor microenvironments).  In order to explore the effect of pH on in vitro release, 232 
(DOX/OA)@H6R6-CS-g-PNVCL powders (5 mg) were fully dissolved in PBS buffer solution (5 233 
mL, pH 7.4) and PBS buffer solution (5 mL, pH 6.5), respectively and the above two solutions 234 
were poured into dialysis tubing (MWCO = 3500 Da), placed in the containers containing the 235 
same PBS solution (100 mL) and shaken at a frequency of 100 oscillations /min in a 37 °C water 236 
bath.  Samples of PBS solution (1mL) were removed from the container at certain time intervals 237 
and supplemented with the same preheated PBS buffer solution (1mL).  The amount of DOX or 238 
OA in the samples was determined by UV-vis spectrophotometry.  The above experiments were 239 
repeated but the temperature was changed to 40 °C in order to explore the effect of temperature on 240 
in vitro drug release.  Each experiment was repeated three times. 241 
 242 
2.5. Cell culture 243 
 244 
SKOV3 cells were cultured in McCoy’s 5A incomplete medium (containing 80 U/mL 245 
penicillin and 0.08 mg/mL streptomycin) supplemented with 10% (v/v) FBS in a relative 246 
humidified atmosphere of 5% CO2 at 37 °C.  HUVEC cells were cultured in DMEM medium 247 
supplemented with 10% (v/v) FBS and 1% (v/v) penicillin-streptomycin in a relative humidified 248 
atmosphere of 5% CO2 at 37 °C.  The controls were cells treated with an equal volume of PBS 249 




2.6. Cell viability 252 
 253 
The cytotoxicity of free DOX, free OA, H6R6-CS-g-PNVCL, DOX@H6R6-CS-g-PNVCL 254 
and (DOX/OA)@H6R6-CS-g-PNVCL in two cell lines (SKOV3 and HUVEC) was evaluated 255 
using the MTT assay.  SKOV3 cells and HUVEC cells were seeded in 96-well plates at a cell 256 
density of 1×104 cells/well and both were incubated until 80% confluent.  Subsequently, free 257 
DOX, free OA, H6R6-CS-g-PNVCL, DOX@H6R6-CS-g-PNVCL and 258 
(DOX/OA)@H6R6-CS-g-PNVCL (dispersed in PBS) at the concentrations of final DOX of 0, 0.5, 259 
1, 2, 5, and 10 μg / mL (the concentrations of OA were set to half of the concentrations of DOX) 260 
were added into the wells and incubated for 24 h.  The cells without treatment were used as 261 
controls.  MTT (20 μL, 5 mg/mL) was added to each well and incubated for 4 h followed by 262 
addition of DMSO (180 μL) to dissolve formazan crystals.  Finally, the absorbance at 570 nm 263 
was measured by a microplate reader (PowerWave XS, Bio-Tek, Winooski, VT, USA).  Each 264 
experiment was performed in triplicate, and the IC50 values of each DOX formulation were 265 
calculated.  266 
In order to visually assess the in vitro antitumor effect, the calcein-AM/PI double-labeling 267 
method was carried out.  SKOV3 cells were seeded into a 24-well plate at the cell density of 268 
1×105 cells/well and incubated overnight in order for the cells to adhere and grow.  The original 269 
medium was discarded, then free DOX, free OA, H6R6-CS-g-PNVCL, 270 
DOX@H6R6-CS-g-PNVCL and (DOX/OA)@H6R6-CS-g-PNVCL (all dispersed in PBS) were 271 
added separately (at concentrations determined according to the IC50 values of the final DOX).  272 
The SKOV3 cells were subsequently incubated with fresh serum-free medium overnight using 273 
untreated cells as controls.  Each well was washed three times with PBS (pH 7.4) and the 274 
SKOV3 cells were stained with a mixed calcein-AM and PI solution for 15 min.  The live cells 275 
(green) and dead cells (red) were distinguished under an inverted fluorescent microscope (DMi8, 276 
Leica, Germany). 277 
The Annexin V-FITC and Propidium Iodide (PI) double-staining method was employed to 278 
determine the proportion of apoptosis.  SKOV3 cells were seeded into 6-well plates at density of 279 
1×106 cells/well and cultivated for the required time for adherence, then treated separately for 4 h 280 
with free DOX, free OA, H6R6-CS-g-PNVCL, DOX@H6R6-CS-g-PNVCL and 281 
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(DOX/OA)@H6R6-CS-g-PNVCL.  The SKOV3 cells were washed three times with PBS (pH 282 
7.4), the cells were collected after digestion with 0.25% trypsin (without EDTA) and termination 283 
with McCoy’s 5A incomplete medium.  The cells were washed twice with PBS (pH 7.4) and then 284 
Binding Buffer (500 μL) was used to re-suspend the cells at a concentration of 1×106 cells/mL, 285 
Annexin V-FITC (5 μL) and PI (5 μL) were added and the cells were incubated for 15 min at RT 286 
(25°C) in the dark.  All the samples were determined within 1 h by flow cytometry (Becton 287 
Dickinson, CA, USA). 288 
 289 
2.7. Cellular uptake  290 
 291 
In order to evaluate the intracellular uptake by the tumor cells, flow cytometry was employed. 292 
SKOV3 cells were seeded into 6-well plates at 1×104 cells/well and allowed to grow for 24 h and 293 
were then incubated with the control, free DOX, free OA, (DOX/OA)@CS-g-PNVCL and 294 
(DOX/OA)@H6R6-CS-g-PNVCL for 4h, respectively. The cells were washed three times with 295 
PBS (pH 7.4), harvested, and then re-suspended in PBS and then the samples were subjected to 296 
flow cytometry analysis (Becton Dickinson, CA, USA). 297 
To examine the cell-penetrating capability of H6R6 and the properties of redox-dependent 298 
targeting the tumor cells, HUVEC cells and SKOV3 cells were visualized and imaged by confocal 299 
laser scanning microscopy (CLSM).  The cells were seeded into 20 mm culture dishes at 1×104 300 
cells/dish and incubated until 80% confluent and the cells were then co-cultured with various 301 
formulations including free DOX, (DOX/OA)@CS-g-PNVCL and 302 
(DOX/OA)@H6R6-CS-g-PNVCL for 2 h, respectively. Separately,  303 
(DOX/OA)@H6R6-CS-g-PNVCL was incubated with cells for 2 h after pre-incubation for 1 h 304 
with GSH (10 mM GSH) solution as a reducing reagent.  All cells were washed three times with 305 
PBS (pH 7.4) and fixed for 15 min with aqueous glutaraldehyde solution (1mL, 2.5% v/v).  The 306 
cell nuclei were stained with Hoechst 33342 solution (0.5 mL, 10 μg / mL) for 15 min, after which 307 
the cells were again washed three times with PBS (pH 7.4) and observed by CLSM (FV1000 308 
microscope, Olympus, Japan). 309 
 310 




Subcutaneous models of SKOV3 tumor-bearing nude mice were established by inoculating 313 
them with a suspension (150 μL, 2×106 cells) of SKOV3 cells in the axillary region of nude mice.  314 
The nude mice were randomized into two groups (8 mice each) when the tumor size reached about 315 
0.15 cm3 in volume. 316 
In order to track the real-time bio-distribution of fluorescence, DiR labeled nanocomposite 317 
(replacing DOX and OA with DiR), free DiR and DiR@H6R6-CS-g-PNVCL were administered 318 
by caudal vein injection with the equivalent dosage of DiR based on mouse body weight per kg.  319 
The mice were anesthetized for real-time fluorescence imaging performed at 1 h, 4 h, 8 h and 24 h 320 
post-injection using a Maestro in vivo imaging system (CRi Inc., U.S.A.).  The mice were then 321 
euthanized and the main organs (heart, liver, spleen, lung and kidney) and tumor regions were 322 
harvested for ex vivo imaging to further study the distribution of the nanocomposite. 323 
 324 
2.9. In vivo antitumor efficacy 325 
 326 
SKOV3 xenograft nude mice models were established by subcutaneous injection as described 327 
above.  When the volume of the tumor grew to around 0.15 cm3, SKOV3 tumor-bearing mice 328 
were randomly assigned into six groups (eight mice each).  The mice in each group were 329 
intravenously injected, every two days, with saline, free DOX, free OA, H6R6-CS-g-PNVCL, 330 
DOX@H6R6-CS-g-PNVCL and (DOX/OA)@H6R6-CS-g-PNVCL through the tail vein.  The 331 
survival times of the mice were recorded and analyzed by Kaplan-Meier methodology.  The 332 
dosages of various formulations were calculated as an equivalent dosage of DOX per kg of mouse 333 
body weight.  Finally, the xenografted nude mice in the different treatment groups were weighed 334 
and the tumor sizes were measured. 335 
 336 
2.10. Pathological evaluation 337 
 338 
For further pathological study, the mice were dissected at the end of the treatment, the tumors 339 
and main organs (heart, liver, spleen, lung and kidney) in different treatment groups were collected 340 
and analyzed by hematoxylin and eosin (H&E) staining.  Furthermore, the tumor tissue sections 341 
from various treatment groups were obtained and stained using terminal deoxynucleotidyl 342 




2.11. Statistical analysis 345 
 346 
Statistical analysis was carried out using either Student’s t-test or one-way analysis of 347 
variance (ANOVA) combined with Tukey’s post-hoc analysis (SPSS software, version 18.0, SPSS 348 
Inc.) where p < 0.05 was considered to be significant (*) and p < 0.01 highly significant (**). 349 
 350 
3. Results and discussion 351 
 352 
3.1. Preparation and characterization of the nanocomposites 353 
 354 
The synthetic route to (DOX/OA)@H6R6-CS-g-PNVCL is shown in Scheme 2. It begins 355 
with fabrication of the preliminary nanocomposite by RAFT polymerization to form the graft 356 
copolymer. H6R6 was then bound to CS-g-PNVCL with the aid of thioglycolic acid and cysteine 357 
to form the triple (redox, pH and temperature) sensitive nanocomposite  (H6R6-CS-g-PNVCL).  358 
Finally, two anticancer agents (DOX and OA) were loaded onto the H6R6-CS-g-PNVCL to obtain 359 
(DOX/OA)@H6R6-CS-g-PNVCL having a DOX loading and encapsulation efficiency of 13.2% 360 
and 78.6%, respectively; the OA values were 7.3% and 69.9%, respectively.  Zeta potential are 361 
provided to demonstrate the load of the drugs in Supplementary information (Fig. S3).  The 362 
(DOX/OA)@H6R6-CS-g-PNVCL NPs retain the thermosensitive properties of PNVCL, showed a 363 
phase transition at 35-42°C with an LCST of 36°C (Fig. 1D). 364 
H6R6-CS-g-PNVCL was characterized by FT-IR spectroscopy, as shown in Fig. 1A and the 365 
major characteristic peaks of CS are observed at 3370 cm-1 (O-H stretch); 1641 cm-1 (amide C=O 366 
str); 1567 cm-1 (amide NH bend); 1629 cm-1 (C=O str of PNVCL); 1439 cm-1 (NVCL -CH2), and 367 
2932 cm-1 (polymeric aliphatic C-H str.).  It is notable that the double bond of NVCL at 1652 368 
cm-1 had disappeared, suggesting that the NVCL monomer had been polymerized.  FT-IR 369 
spectrum of CS-RAFT and CS-g-PNVCL are provided in Supplementary information (Fig. S1).  370 
1H NMR spectra of CS-RAFT is provided in Supplementary information (Fig. S2).  13C NMR 371 
spectra of N-CS-RAFT exhibited signals at 168.7-172.3 ppm (the carbonyl carbon as Fig. 1B), 372 
indicating the successful introduction of RAFT reagent.  The TGA of CS and CS-RAFT are 373 
provided (Fig. S4), showing the successful formation of CS-RAFT and the grafting rate of RAFT 374 
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reagent is 21.83%. The above data strongly indicates the formation of CS-g-PNVCL but there was 375 
no obvious evidence that the H6R6 peptide was grafted onto the modified CS.  Therefore, 1H 376 
NMR spectra was used to further confirm the successful preparation of H6R6-CS-g-PNVCL (Fig. 377 
1C).  Signals at 3.1-3.8 ppm (glucosamine units H-3 to H-6, H-6’ of CS); 1.9-2.6 ppm (multiple 378 
peaks 2H and -COCH2- of the PNVCL units); 1.3-1.7 ppm (-NH2-CH2- of arginine in H6R6 379 
peptide); 8.3 ppm (imidazole ring from histidine in H6R6 peptide). All demonstrated the 380 
successful synthesis of H6R6-CS-g-PNVCL. 381 
The representative transmission electron microscopy (TEM) image of 382 
(DOX/OA)@H6R6-CS-g-PNVCL showed that the sample presented uniform and typical spherical 383 
morphology with an average size of around 190 nm (Fig. 1E), corresponding to the scanning 384 
electron microscopy (SEM) results (Fig. 1F).  Additionally, dynamic light scattering (DLS) 385 
measurements revealed that the average hydrodynamic diameter of the 386 
(DOX/OA)@H6R6-CS-g-PNVCL NPs was approximately 235 nm (Fig. 1G), which is slightly 387 
bigger than that in the corresponding TEM and SEM micrographs as a result of the samples 388 
having been dried before observation.  Fig. 1G revealed that the size distribution of unloaded 389 
H6R6-CS-g-PNVCL NPs approximated 221 nm, suggesting the successful loading of drugs for 390 
(DOX/OA)@H6R6-CS-g-PNVCL NPs. Importantly, the size of 391 
(DOX/OA)@H6R6-CS-g-PNVCL NP can meet the required conditions of the EPR effect.  392 
 393 
 394 
Scheme 2. The synthesis of (DOX/OA)@H6R6-CS-g-PNVCL NPs. (1) Acetic anhydride, rt, 4 h; (2) DDACT, 395 
DCC, DMAP, rt, 40 h; (3) NVCL, AIBN, 60°C, 24 h; (4) Hydrolysis, rt; (5) Cys-H6R6, thioglycolic acid, EDC, 396 




Fig. 1. Characterization of NPs: (A) FT-IR spectrum of CS, NVCL, Cys-H6R6, (DOX/OA)@H6R6-CS-g-PNVCL. 399 
(B) 13C NMR spectra of N-CS-RAFT in DMSO-d6. (C) 1H NMR spectrum of (DOX/OA)@H6R6-CS-g-PNVCL 400 
in D2O. (D) The change in absorbance at 500 nm of an aqueous solution of (DOX/OA)@H6R6-CS-g-PNVCL with 401 
temperature. (E) TEM and (F) SEM images of (DOX/OA)@H6R6-CS-g-PNVCL NPs.  (G) Size distribution of 402 
H6R6-CS-g-PNVCL and (DOX/OA)@H6R6-CS-g-PNVCL NPs determined by DLS. 403 
 404 
3.2. Temperature/pH-triggered controlled release 405 
 406 
The release profiles of DOX and OA from (DOX/OA)@H6R6-CS-g-PNVCL NPs were 407 
investigated at 37 °C and 40 °C and pH values of 7.4 and 6.5.  As shown in Figs. 2A and B, the 408 
DOX and OA release behaviors from (DOX/OA)@H6R6-CS-g-PNVCL NPs are affected by both 409 
temperature and pH.  The general characteristic was from rapid release to slow release of DOX 410 
and OA at different temperature and pH values within 72 h and the cumulative release of DOX 411 
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from the nanocomposite reached about 74.6% (40 °C, pH=6.5), but only 24.7% at 37 °C and  412 
pH=7.4.  The cumulative release of OA from the nanocomposite was 63.2% (40 °C, pH=6.5), but 413 
only 21.1% at 37°C, pH=7.4.  It is postulated that the PNVCL and CS from 414 
(DOX/OA)@H6R6-CS-g-PNVCL responded to the temperature and pH of the tumor 415 
microenvironment, resulting in the disintegration of the nanocomposite. Interestingly, a similar 416 
release trend was found for DOX and OA under similar conditions, indicating that both drugs were 417 
loaded into the nanocomposite in a similar way.  These results show that the nanocomposite 418 
possesses the properties of temperature/pH-dependent triggered release for two these drugs in the 419 
tumor microenvironment. 420 
 421 
Fig. 2. In vitro cumulative release of (A) DOX and (B) OA from (DOX/OA)@H6R6-CS-g-PNVCL NPs at 422 
different temperatures and pH values.  Each value is shown as mean ± SD (n = 3). 423 
 424 
3.3. Cytotoxicity studies 425 
 426 
Good biocompatibility is a prerequisite for successful biological applications, so in vitro 427 
cytotoxicity of various formulations on HUVEC and SKOV3 cells was studied using the MTT 428 
assay.  The results suggested that blank H6R6-CS-g-PNVCL had a slight cytotoxic effect on 429 
tumor cells, but were essentially nontoxic on normal cells (> 90% cell viability).  The 430 
cytotoxicity of free DOX was dose-dependent, showing more cytotoxicity toward normal cells 431 
compared to that of all other treatment groups (Fig. 3A).  Meanwhile, both 432 
DOX@H6R6-CS-g-PNVCL and (DOX/OA)@H6R6-CS-g-PNVCL treatment groups exhibited 433 
much more cytotoxicity toward tumor cells than normal cells (Fig. 3A and B).  However, a 434 
significant enhanced antitumor effect was achieved and attributed to the combined activity of 435 
DOX and OA (Fig. 3B).  436 
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The in vitro antitumor efficacy was visually assessed by distinguishing between live cells 437 
(green) and dead cells (red).  As shown in Fig. 3C, the DOX@H6R6-CS-g-PNVCL treatment 438 
group showed more apoptosis than the free DOX group, indicating that H6R6-CS-g-PNVCL could 439 
deliver the anti-tumor drugs to the cells more efficiently.  Notably, the most apoptotic cells were 440 
observed in the (DOX/OA)@H6R6-CS-g-PNVCL treatment group compared to other groups (Fig. 441 
3C), echoing the MTT assay results (Fig. 3B).  442 
To further determine the antitumor effectiveness of co-delivery and mono-delivery 443 
formulations against SKOV3 cells, the sum of the rates of early and late apoptosis was calculated 444 
as the total apoptotic ratios of SKOV3 cells.  As shown in Fig. 3D, the results suggested that the 445 
(DOX/OA)@H6R6-CS-g-PNVCL group had the highest total apoptosis ratio (91.3%) compared 446 
to the controls (2.33%), H6R6-CS-g-PNVCL (4.67%), free OA (5.23%), free DOX (7.75%) and 447 
DOX@H6R6-CS-g-PNVCL (32.21%).  Additionally, the DOX@H6R6-CS-g-PNVCL treatment 448 
group showed a lower level of cell apoptosis (32.21%) compared to the 449 
(DOX/OA)@H6R6-CS-g-PNVCL treatment group (91.3%).  These results indicate that 450 
(DOX/OA)@H6R6-CS-g-PNVCL possess the most potent tumor cell-killing capability and the 451 
antitumor efficacy of co-delivery is better than that of mono-delivery. 452 
Two conclusions can be drawn from the above data: (1) H6R6-CS-g-PNVCL possesses good 453 
biocompatibility for normal cells and can be considered as an antitumor complement in terms of 454 
its slight cytotoxicity against tumor cells and (2) (DOX/OA)@H6R6-CS-g-PNVCL had relatively 455 
higher cytotoxicity toward tumor cells than DOX@H6R6-CS-g-PNVCL, indicating a significant 456 





Fig. 3. Cell viability of (A) HUVEC and (B) SKOV3 cells after incubation for 24 h with free DOX, free OA, 460 
H6R6-CS-g-PNVCL, DOX@H6R6-CS-g-PNVCL and (DOX/OA)@H6R6-CS-g-PNVCL. Data are expressed as 461 
mean ± SD ( n =3); * p < 0.05, ** p < 0.01.  (C) Live (green) /dead (red) cell assay of SKOV3 cells treated with 462 
the above various formulations: Ⅰ Control; Ⅱ Free DOX; Ⅲ  Free OA; Ⅳ  H6R6-CS-g-PNVCL; Ⅴ 463 
DOX@H6R6-CS-g-PNVCL; Ⅵ DOX/OA)@H6R6-CS-g-PNVCL. (scale bars =100 μm).  (D) Flow cytometry 464 
analysis of SKOV3 cell apoptosis induced by free DOX, free OA, H6R6-CS-g-PNVCL, 465 





3.4. Reduction-responsive controlled intracellular uptake 469 
 470 
In order to evaluate the internalization of tumor cells for various treatment groups, 471 
intracellular uptake was measured by flow cytometry and CLSM.  According to the results of 472 
flow cytometry, the uptake curve of the (DOX/OA)@H6R6-CS-g-PNVCL group shifted more to 473 
the right than that of the control, free DOX, free OA and (DOX/OA)@CS-g-PNVCL groups, 474 
revealing that the H6R6-functionalized NPs were taken up by SKOV3 cells due to the superior 475 
penetrating function of the H6R6 peptide (Fig. 4A). 476 
CLSM results showed that red fluorescence signals of HUVEC cells incubated with 477 
(DOX/OA)@CS-g-PNVCL and (DOX/OA)@H6R6-CS-g-PNVCL were quite weak.  However, 478 
SKOV3 cells incubated with (DOX/OA)@H6R6-CS-g-PNVCL exhibited a much higher red 479 
fluorescence signal compared to those treated with (DOX/OA)@CS-g-PNVCL, indicating that 480 
H6R6-functionalized NPs could target tumor cells, rather than normal cells (Fig. 4B).  Using 481 
H6R6-functionalized NPs pretreated with GSH to culture cells, the red fluorescence signals of 482 
HUVEC cells and SKOV3 cells were almost invisible (Fig. 4B) because when 483 
H6R6-functionalized NPs reach normal cells, they rarely stay there due to the cell-penetrating 484 
function of H6R6 peptide.  In contrast, once H6R6-functionalized NPs reach tumor cells, the 485 
H6R6 peptide is released via breakage of the -S-S- bond under the reductive tumor 486 
microenvironment, causing NPs to stay in the tumor cells.  These results indicate the 487 
cell-penetrating capability of the H6R6 peptide and the function of reduction-responsive 488 




Fig. 4. Cell uptake studies.  (A) Flow cytometry analysis of internalization of free DOX, free OA, 491 
(DOX/OA)@CS-g-PNVCL and (DOX/OA)@H6R6-CS-g-PNVCL on SKOV3 cells.  (B) CLSM images of 492 
HUVEC cells and SKOV3 cells after incubation with (Ⅰ) free DOX; (Ⅱ) (DOX/OA)@CS-g-PNVCL; (Ⅲ) 493 




3.5 In vivo biodistribution 496 
 497 
In order to study in vivo biodistribution of the H6R6-functionalized NPs, fluorescence DiR 498 
labeled NPs were observed.  As shown in Fig. 5A, the DiR labeled NPs group presented strong 499 
fluorescence at the tumor site in the first 1h, whereas the fluorescence of free DiR group was not 500 
observed at the tumor site within the same period.  All fluorescence decreased over time as a 501 
result of metabolism, but some distinct fluorescence could still be seen even 24 h after injection.  502 
After 24 h, the free DiR group showed accumulation in other areas in addition to the tumor region 503 
whilst the DiR labeled NPs group displayed a higher accumulation in the tumor region. 504 
Additionally, ex vivo imaging results showed distributions of free DiR and DiR labeled NPs in 505 
major organs and tumors, in which free DiR existed in major healthy organs as well as the tumor 506 
areas as a result of non-specific biodistribution but DiR labeled NPs mainly accumulated in tumor 507 
areas with little liver deposition (Fig. 5B).  According to the quantitative region of interest (ROI) 508 
analysis, the accumulation in the tumor of DiR labeled NPs was 2.25-fold higher than that of free 509 
DiR (Fig. 5C).  These results demonstrate that H6R6-functionalized NPs are feasible for in vivo 510 




Fig. 5. (A) In vivo fluorescence images of SKOV3 xenograft nude mice after i.v. injection of free DiR and 513 
DiR@H6R6-CS-g-PNVCL NPs (images taken from different mice).  The red circles indicate the tumor sites.  (B) 514 
Ex vivo fluorescence images and (C) statistical analysis of hearts (H), livers (Li), spleens (S), lungs (Lu), kidneys 515 
(K) and tumors (T).  Data are given as mean ± SD (n = 8 ).  * p < 0.05, ** p < 0.01. 516 
 517 
3.6 In vivo therapeutic efficacy evaluation 518 
 519 
Encouraged by the above results, the in vivo antitumor effect of various treatments were 520 
studied.  The saline group showed rapid tumor growth over the 30 d, while almost all of the other 521 
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treatments inhibited tumor growth (Fig. 6A) due to the presence of CS from blank 522 
H6R6-CS-g-PNVCL hiving some anti-tumor effects.  The tumor growth inhibition using 523 
(DOX/OA)@H6R6-CS-g-PNVCL and DOX@H6R6-CS-g-PNVCL treatment groups were found 524 
to be the best and co-delivery, in comparison to mono-delivery, achieved a significantly enhanced 525 
antitumor efficacy (Fig. 6A).  Additionally, the body weights of the mice from various treatment 526 
groups showed no obvious differences, except for the free DOX treatment group which was 527 
probably due to high systemic toxicity (Fig. 6B).  Fig. 6C showed the mean survival duration of 528 
the mice in the various groups with saline being 43 days, the H6R6-CS-g-PNVCL group 44 days, 529 
the free OA group 49 days and the free DOX group 38 days.  In contrast, the mice treated with 530 
(DOX/OA)@H6R6-CS-g-PNVCL and DOX@H6R6-CS-g-PNVCL survived for over 60 days 531 
with survival rates of around 64% and 42%, respectively.  These results thereby verify the 532 
outstanding in vivo antitumor effect of (DOX/OA)@H6R6-CS-g-PNVCL NPs, suggesting that the 533 
co-delivery system has a better performance on inhibiting tumor growth than that of 534 
mono-delivery.  535 
 536 
Fig. 6. In vivo antitumor effects of different treatments.  (A) Tumor growth curves of the mice treated with 537 
different formulations.  (B) Body weights of mice in different treatment groups as indicated over 30 days.  (C) 538 




3.7 Pathological evaluation 541 
 542 
The H&E staining images (Fig. 7A) indicated that the (DOX/OA)@H6R6-CS-g-PNVCL 543 
treatment group exhibited the highest detrimental effect on tumor tissue, while there was no 544 
evidence of damage in the main organs, implying low systemic toxicity.  Except for the free 545 
DOX group, no significant pathological variations were observed in the main organs for the 546 
remaining treatment groups.  However, free OA and DOX@H6R6-CS-g-PNVCL groups 547 
displayed some abnormal tissue morphologies in tumors, meaning that OA and 548 
DOX@H6R6-CS-g-PNVCL were also somewhat toxic to tumors but not normal organs. 549 
TUNEL staining images were used for further evaluation of the toxicity in tumor tissue in the 550 
different treatment groups.  As displayed in Fig. 7B, normal cell nuclei were stained dark blue 551 
while the apoptotic ones were brown.  In line with the anti-tumor results in vivo, the largest areas 552 
of apoptosis were observed in the (DOX/OA)@H6R6-CS-g-PNVCL treatment group.  553 
Furthermore, the group of mono-delivery of DOX also showed many apoptotic cells, but fewer 554 
than that shown by co-delivery of DOX and OA.  Quantitative analyses of the TUNEL staining 555 
images (Fig. 7C) showed the apoptosis rates of tumor cells are 7% for saline, 12% for 556 
H6R6-CS-g-PNVCL, 20% for free OA, 46% for free DOX, 63% for DOX@H6R6-CS-g-PNVCL, 557 
and 86% for the (DOX/OA)@H6R6-CS-g-PNVCL treatment group.  Overall, these results fully 558 
demonstrate the rationality of the design of this triple sensitive nanocomposite and the superiority 559 







Fig. 7.  Pathological analyses.  (A) Histological analysis of the main organ and tumor slices from various 565 
treatments by H&E staining, scale bar = 100 μm.  (B) TUNEL staining of tumor slices, scale bar = 50 μm.  (C) 566 
Statistical analysis of the TUNEL positive rates. (ⅠSaline;Ⅱ H6R6-CS-g-PNVCL; Ⅲ Free OA; Ⅳ Free DOX; 567 
Ⅴ DOX@H6R6-CS-g-PNVCL; Ⅵ (DOX/OA)@H6R6-CS-g-PNVCL).  Data are shown as mean ± SD ( n =5 ). 568 




4. Conclusion 571 
 572 
In summary, the development of a triply sensitive nanocomposite that possesses the ability of 573 
selective residence in tumor cells due to presence of the H6R6 peptide and reduction-responsive 574 
disulfide bonds (-S-S-) is described.  Remarkable is the influence of pH or temperature on DOX 575 
and OA release profiles from nanocomposite based on chitosan.  The release characteristics of 576 
DOX and OA are from rapid release to slow release, then reaching a plateau at different 577 
temperature and pH.  The cumulative release of DOX or OA is higher at acidic pH (6.5) and 578 
higher temperature (40°C) than at physiological pH (7.4) and temperature (37°C).   The release 579 
of DOX is maximum (about 74.6%) at specific pH and temperature of simulated tumor 580 
microenvironment (pH=6.5, 40 °C), while DOX release is minimal (about 24.7%) at physiological 581 
pH and temperature (pH=7.4, 37 °C).  The cumulative release of OA from the nanocomposite is 582 
63.2% (pH=6.5, 40 °C), but only 21.1% (pH=7.4, 37°C).  The system demonstrates the property 583 
of triggering DOX and OA release as a result of temperature/pH dual-responsive decomposition 584 
behavior.  The co-delivery system demonstrates fully the advantage of tumor microenvironment 585 
characteristics to achieve targeted and controlled release.  Both in vitro and in vivo studies show 586 
that the co-delivery system exhibits greater chemotherapeutic effects compared to monotherapy 587 
and such a co-delivery strategy shows great promise for enhanced development in cancer 588 
chemotherapy.  This triple sensitive co-delivery system could be applied in treatment of a variety 589 
of solid tumor types to overcome many difficulties of conventional chemotherapy. 590 
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